英国的NHS将为面部白风的青少年和成年人提供 ruxolitinib 乳液,这是英国首次批准的治疗方法. England’s NHS will fund ruxolitinib cream for teens and adults with facial vitiligo, the first approved treatment in the UK.

英格兰NHS现将资助12岁及以上非节段性白癜风患者使用鲁索替尼乳膏（Opzelura），这是英国首个获批该病的治疗方案。 The NHS in England will now fund ruxolitinib cream (Opzelura) for patients aged 12 and over with non-segmental vitiligo affecting the face, marking the first approved treatment for the condition in the UK. NICE在修订定价协议后批准了日本投资公司专题抑制剂,指出临床效益和性价比很高。 NICE approved the topical JAK inhibitor after a revised pricing agreement, citing strong clinical benefits and value for money. 乳霜每天施用两次,通过将免疫系统对甲状腺素的攻击作为目标,帮助恢复皮肤色素,试验显示比安慰剂的调整幅度要大得多。 The cream, applied twice daily, helps restore skin pigmentation by targeting the immune system’s attack on melanocytes, with trials showing significantly greater repigmentation than placebo. 推荐给那些对一线治疗没有反应或不能使用第一线治疗的人。 It is recommended for those who haven’t responded to or cannot use first-line treatments. 该决定受到病人代言人的欢迎,可以使80 000多人受益,并解决长期未得到满足的医疗需求,特别是对那些皮肤更深和有重大社会心理影响的人而言。 The decision, welcomed by patient advocates, could benefit over 80,000 people and addresses a long-standing unmet medical need, particularly for those with darker skin tones and significant psychosocial impacts.